Abdominal Neoplasms - 350 Studies Found Recruiting : Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers : Cervical Adenosarcoma Cervical Adenosquamous Carcinoma Cer : 2013-12-19 : Biological: Bevacizumab Given Suspended : GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer : Epithelial Ovarian Cancer Fallopian Tube Cancer Primary Pe : 2013-12-02 : Drug: Ganetespib Drug: Paclitaxel Withdrawn : Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission : Recurrent Fallopian Tube Cancer Recurrent Ovarian Epithelial Cancer Biological: ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine Recruiting : Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer : Recurrent Uterine Corpus Cancer Recurrent Fallopian Tube Cancer Procedure: therapeutic conventional surgery Completed : Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer : Relapsed Epithelial Ovarian Cancer Relapsed Primary Peritoneal Cancer Drug: Birinapant Not yet recruiting : An Observational Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer : Ovarian Cancer, Peritoneal Neoplasms : 2013-08-27 Active, not recruiting : A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) : Ovarian Cancer Epithelial Ovarian Cancer Fallopian Tube Ca : 2013-06-20 : Drug: Oral rucaparib 600 mg BID Other Names: Recruiting : Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer : Recurrent Epithelial Ovarian Cancer Recurrent Fallopian Tube Cancer Low-grade Serous Ovarian Cancer Low-grade Serous Fallopian Tube Cancer Drug: MEK162, MEK inhibitor; oral Recruiting : A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer : Ovarian Neoplasms Peritoneal Neoplasms Fallopian Tube Neop : 2013-05-01 : Drug: Trabectedin 1.1 mg/m2 ad <<< Previous | Next >>>
